Stephen Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Dr. Jessica Lin discusses adjuvant targeted therapy for resected NSCLC – how far are we comfortable extrapolating?
Do we need phase III studies for all targets? Consider the cost of waiting.”
See gallery below.
You can also read: Savolitinib and Osimertinib Combination for NSCLC Moves Closer to Approval in Europe and Japan.
